RPRX
Royalty Pharma Plc
NASDAQ: RPRX · HEALTHCARE · BIOTECHNOLOGY
$54.87
-0.76% today
Updated 2026-06-12
Market cap
$31.60B
P/E ratio
28.88
P/S ratio
12.95x
EPS (TTM)
$1.90
Dividend yield
1.62%
52W range
$34 – $57
Volume
3.6M
Royalty Pharma Plc (RPRX) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed RPRX price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$54.87
Today
Analyst consensus
$59.25
+7.98% · 12M
2030 Base
$76.76
+39.89% future
NPV today
$56.92
@ 7% WACC
12 analysts:
7 Buy1 Hold0 Sell
Management guidance
Royalty Pharma guided 2026 portfolio receipts of $3,275M-$3,425M (midpoint $3,350M), representing ~41% growth from 2025's $2,380M. Management raised 2026 revenue guidance post-Q1 earnings and emphasized aggressive capital deployment ($528M in Q1 2026 alone) into new royalty acquisitions. CEO Pablo Legorreta has positioned the company as the world's largest buyer of pharmaceutical royalties with $25B+ deployed historically, targeting continued high-teens to mid-20s organic growth supplemented by M&A.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
RPRX · Royalty Pharma Plc · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$38.60
NPV today: $28.63
Base case (2030)
$76.76
NPV today: $56.92
Bull case (2030)
$153.07
NPV today: $113.51
WallStSmart.com
RPRX financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $2.4B | $3.4B | $3.9B | $4.5B | $5.0B | $5.7B |
| Revenue growth | 5.1% | 40.8% | 16.4% | 14.1% | 13.5% | 12.9% |
| Net margin | — | 70.2% | 66.8% | 63.7% | 62.4% | 60.9% |
| EPS | $3.75 | $5.29 | $5.85 | $6.35 | $7.05 | $7.75 |
| Diluted shares | — | 445M | 445M | 446M | 447M | 448M |
| Net debt | — | $7.04B | $5.56B | $3.88B | $1.96B | $-199.76M |
| P/S multiple | — | 6.0x | 6.0x | 6.0x | 6.0x | 6.0x |
| Implied price (base) | — | $29.37 | $40.04 | $51.13 | $63.36 | $76.76 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $5.7B | $5.7B | $5.7B |
| P/S multiple | 3.0x | 6.0x | 12.0x |
| Diluted shares | 448M | 448M | 448M |
| Net debt | $-199.76M | $-199.76M | $-199.76M |
| Implied P/E † | 5x | 10x | 20x |
| 2030 Price | $38.60 | $76.76 | $153.07 |
| NPV @ 7% | $28.63 | $56.92 | $113.51 |
† Implied P/E: Multiples remain elevated across all three scenarios because RPRX is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $76.76 base case
RPRX catalysts and risks
Growth catalysts
+ Q1 2026 showed 10.97% portfolio receipt growth with $528M capital deployment; continued acquisition pipeline execution
+ $500M co-funding agreement with Johnson & Johnson (2026-2027) for JNJ-4804 development signals confidence in portfolio growth
+ Acquisition of remaining royalty interest in Roche's Evrysdi ($240M) and Zymeworks financing ($250M royalty-backed note) demonstrates active inorganic growth strategy
+ Favorable regulatory and clinical catalysts expected to positively impact future cash flows per management Q1 2026 commentary
+ Dividend raised (Q2 2026: $0.235/share) signals management confidence in sustained cash generation and capital allocation flexibility
Key risks
- Patent cliff risk: 5-10 key drugs represent outsized percentage of royalty streams; loss or generic competition on flagship products could materially impact receipts
- Drug pricing reform risk: US and international price controls (IRA negotiation provisions, international reference pricing) directly compress royalty economics
- Concentration risk: portfolio heavily weighted to oncology and specialty pharma; loss of single-digit number of large royalties could reduce revenue 15-20%
- High leverage: $8.95B total debt with LT Debt/Equity of 1.25 constrains financial flexibility and increases refinancing risk in higher-rate environment
- Dividend not fully covered by FCF: payout ratio 49.4% but company relies on debt to fund both acquisitions and shareholder returns
- M&A execution risk: aggressive capital deployment strategy requires consistent deal flow at acceptable ROI; prolonged dry spell could delay growth targets
Methodology · Royalty Pharma Plc 2030 stock forecast model
Royalty Pharma Plc 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 12 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (1% cumulative for RPRX by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($-199.76M by 2030) |
| 3. Time value | NPV calculated using 7% WACC (CAPM: beta 0.396) |
| 4. Multiple framework | P/S compresses with scale: bear 3.0x / base 6.0x / bull 12.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 20, 2026.
RPRX price target FAQ
What is the RPRX price target for 2030?
WallStSmart's Royalty Pharma Plc 2030 base case is $76.76 per share, with a bull case of $153.07 and bear case of $38.60. The NPV of the base case discounted to today at 7% WACC is $56.92.
How is the Royalty Pharma Plc 2030 stock forecast calculated?
The RPRX 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the RPRX price target account for dilution?
Royalty Pharma Plc is projected to grow diluted share count from 443M to 448M by 2030 (a 1% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 1%.
What is the analyst consensus on RPRX stock?
12 analysts cover RPRX with an average 12-month price target of $59.25. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.